Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Sep;31(9):1312.
doi: 10.1136/ijgc-2021-002941. Epub 2021 Jul 28.

Low grade endometrioid endometrial cancer: complexities beyond p53abn

Russell R Broaddus  1 , Katherine C Kurnit  2
Affiliations
Comment

Low grade endometrioid endometrial cancer: complexities beyond p53abn

Russell R Broaddus et al. Int J Gynecol Cancer. 2021 Sep.
No abstract available

Keywords: endometrial neoplasms; pathology; uterine cancer.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Comment on

References

    1. Jamieson A, Thompson EF, Huvia J, Gilks BC, McAlpine JN. p53abn endometrial cancer: understanding the most aggressive endometrial cancers in the era of molecular classification. Int J Gynecol Cancer 2021; 31: 907–913. - PubMed
    1. Kurnit KC, Kim GN, Fellman BM, Urbauer DL, Mills GB, Zhang W, Broaddus RR. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence. Mod Pathol 2017; 30: 1032–1041. - PMC - PubMed
    1. Costigan DC, Dong F, Nucci MR, Howitt BE. Clinicopathologic and immunohistochemical correlates of CTNNB1 mutated endometrial endometrioid carcinoma. Int J Gynecol Pathol 2020; 39: 119–127. - PubMed
    1. Moroney MR, Davies KD, Wilberger AC, Sheeder J, Post MD, Berning AA, Fisher C, Lefkowits C, Guntupalli SR, Behbakt K, Corr BR. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers. Gynecol Oncol 2019; 153: 517–520. - PMC - PubMed
    1. Backes FJ, Haag J, Cosgrove CM, Suarez A, Cohn DE, Goodfellow PJ. Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: a prognostic biomarker. Cancer 2019; 125: 398–405. - PubMed